文献速递系统性红斑狼疮

羟氯喹减量或停药后的复发:来自系统性狼疮国际合作诊所(SLICC)起始队列的结果

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
PubMed 文献 · Ann Rheum Dis · 2021-12-15

基于SLICC起始队列33个中心1999—2019年纳入的1460例SLE患者的前瞻性数据,评估羟氯喹减量或停药后首次复发风险。与维持治疗相比,减量组和停药组首次复发的aHR分别为1.20(95%CI 1.04~1.38)和1.56(95%CI 1.31~1.86)。泼尼松使用与各亚队列复发风险增加超过1.5倍相关,低教育水平者在停药后复发风险尤其高(aHR 1.43,95%CI 1.09~1.87)。

要点

  • 羟氯喹减量组首次SLE复发aHR 1.20(95%CI 1.04~1.38),停药组aHR 1.56(95%CI 1.31~1.86),均高于维持组。
  • 低教育水平者停药后复发风险aHR 1.43(95%CI 1.09~1.87)。
  • 基线时使用泼尼松者在所有羟氯喹亚队列中复发风险增加超过1.5倍。

核心结论

  • 与维持羟氯喹治疗相比,羟氯喹减量或停药后SLE复发风险更高;维持、减量或停药的决定可能对不同亚组产生不同影响,包括使用泼尼松者和/或低教育水平者。
  • 作者认为进一步研究特殊人群(如老年人)可能有帮助。

研究设计与样本

  • 分析SLICC前瞻性起始队列数据,1999—2019年从33个中心在SLE诊断后15个月内纳入并每年随访。
  • 共纳入1460例起始使用羟氯喹的患者(90%为女性)。
  • 比较初始羟氯喹剂量维持期、首次减量后和首次停药后人时;估计至首次复发时间,复发定义为需后续治疗升级、SLE疾病活动指数-2000增加≥4分或因SLE住院。
  • 采用校正HR(aHR)及95%CI评估减量/停药(对照维持)与复发的关联;并在各羟氯喹亚队列中分别进行多变量风险回归识别复发相关因素。

主要发现

  • 与羟氯喹维持组相比,减量组首次SLE复发aHR为1.20(95%CI 1.04~1.38),停药组aHR为1.56(95%CI 1.31~1.86)。
  • 低教育水平患者停药后复发风险尤其高(aHR 1.43,95%CI 1.09~1.87)。
  • 基线时使用泼尼松与所有羟氯喹亚队列中复发风险增加超过1.5倍相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论提出进一步研究特殊人群(如老年人)可能有帮助。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate systemic lupus erythematosus (SLE) flares following hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance. METHODS: We analysed prospective data from the Systemic Lupus International Collaborating Clinics (SLICC) cohort, enrolled from 33 sites within 15 months of SLE diagnosis and followed annually (1999-2019). We evaluated person-time contributed while on the initial HCQ dose ('maintenance'), comparing this with person-time contributed after a first dose reduction, and after a first HCQ discontinuation. We estimated time to first flare, defined as either subsequent need for therapy augmentation, increase of ≥4 points in the SLE Disease Activity Index-2000, or hospitalisation for SLE. We estimated adjusted HRs (aHRs) with 95% CIs associated with reducing/discontinuing HCQ (vs maintenance). We also conducted separate multivariable hazard regressions in each HCQ subcohort to identify factors associated with flare. RESULTS: We studied 1460 (90% female) patients initiating HCQ. aHRs for first SLE flare were 1.20 (95% CI 1.04 to 1.38) and 1.56 (95% CI 1.31 to 1.86) for the HCQ reduction and discontinuation groups, respectively, versus HCQ maintenance. Patients with low educational level were at particular risk of flaring after HCQ discontinuation (aHR 1.43, 95% CI 1.09 to 1.87). Prednisone use at time-zero was associated with over 1.5-fold increase in flare risk in all HCQ subcohorts. CONCLUSIONS: SLE flare risk was higher after HCQ taper/discontinuation versus HCQ maintenance. Decisions to maintain, reduce or stop HCQ may affect specific subgroups differently, including those on prednisone and/or with low education. Further study of special groups (eg, seniors) may be helpful.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Almeida-Brasil CC, Hanly JG, Urowitz M, et al. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2021. PMID: 34911705. doi:10.1136/annrheumdis-2021-221295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。